BMY241004C49000
- 2.70
- 0.000.00%
Bristol-Myers Squibb Newsroom
Hold Rating on Bristol-Myers Squibb Amid Market Challenges and Strategic Execution Risks
BMO Capital raises bristol-myers squibb's target price to $53.
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $37 to $60
Bristol-Myers Squibb Analyst Ratings
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $37 to $57
BMO Capital Adjusts Price Target on Bristol-Myers Squibb to $53 From $48, Maintains Market Perform Rating
Truist Financial Gives a Buy Rating to Bristol-Myers Squibb (BMY)
Bristol-Myers Squibb: Hold Rating Amid New Schizophrenia Drug Launch and Patent Expiries
Bristol-Myers Squibb: Sell Rating Justified by Market Challenges and Drug Uptake Concerns
Bristol-Myers Squibb's Cobenfy: A Balanced Hold Rating Amidst FDA Approval and Market Uncertainties
Sell Rating on Bristol-Myers Squibb Amid Competitive Pressures and Pricing Concerns
Jefferies Adjusts Bristol-Myers Squibb Price Target to $53 From $51, Maintains Hold Rating
Bristol-Myers Squibb Analyst Ratings
BMO Capital Maintains Market Perform on Bristol-Myers Squibb, Maintains $48 Price Target
Bristol-Myers Squibb: Hold Rating Justified by Market-Reflected Approval of KarXT Despite Promising Clinical Data
Goldman Sachs Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $57
Bristol-Myers Squibb Analyst Ratings
Cantor Fitzgerald Reiterates Neutral on Bristol-Myers Squibb, Maintains $50 Price Target
Truist Financial Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating
Truist Financial Remains a Buy on Bristol-Myers Squibb (BMY)